Trials / Recruiting
RecruitingNCT02090530
Precision Cancer Medicine for Advanced Cancer Through High-throughput Sequencing
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,000 (estimated)
- Sponsor
- Ohio State University Comprehensive Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Precision Cancer Medicine for Advanced Cancer Through High-throughput Sequencing
Detailed description
This study supports the collection of tumor specimens for CLIA-certified genomic testing and research testing in parallel. CLIA-certified tests have established measurements of accuracy and precision which allow for return of results. This study does not involve treatment, only testing, which could be used to meet eligibility criteria in other trials or therapies. This study includes a registry for longitudinal evaluation of patients whose cancer has FGFR mutations such as cholangiocarcinoma, pancreatic cancer, and others (telehealth).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Biospecimen collection | Specimens to be collected include a fresh tumor biopsy, previously obtained tumor specimens or blocks (if available), whole blood, serum, plasma and buccal smear. |
Timeline
- Start date
- 2013-11-04
- Primary completion
- 2027-12-31
- Completion
- 2027-12-31
- First posted
- 2014-03-18
- Last updated
- 2026-04-08
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02090530. Inclusion in this directory is not an endorsement.